MIST · Milestone Pharmaceuticals Inc. · Metrics
Market Cap
$80.70M
Shares
124.50M
Volume · Oct 23
1.58M
Avg daily vol (3M)
1.42M
MIST metrics
63 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.65
Market cap
$80.70M
Price action
20 metricsPrice change (1W)
-8.4%
Price change (30D)
-17.8%
Price change (3M)
-44.1%
Price change (6M)
-65.7%
Price change (YTD)
-67.9%
Price change (1Y)
-65.7%
Trailing year
Price change (5Y)
-88.3%
52-week high
$2.95
52-week low
$0.65
Change from 52-week high
-78.0%
Change from 52-week low
+0.0%
Annualized volatility
74.2%
Annualized volatility (3M)
70.4%
Beta
2.4
RSI (14D)
30.8
Price vs SMA 50
-30.1%
Price vs SMA 200
-53.9%
Avg volume (3M)
1.42M
Relative volume
1.1
Average dollar volume
$1.42M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
124.50M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
4.4
reciprocal yield 22.6%
FCF yield
-76.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-104.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-12
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$78.38M
Net income (TTM)
−$84.01M
Trailing 12 months
Diluted EPS (TTM)
$-0.65
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+68.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-461.1%
Return on assets
-46.3%
Debt / equity
3.2
Current ratio
8.1
EBITDA (TTM)
−$78.21M
Free cash flow (TTM)
−$61.65M
Quick ratio
7.9
Interest coverage
-7.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$111.40M
Latest balance sheet
Cash & equivalents
$169.73M
Total assets
$181.62M
Total debt
$59.21M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$61.29M
Capital expenditures (TTM)
$356,000
R&D (TTM)
$16.22M
SG&A (TTM)
—
Stock compensation (TTM)
$7.42M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
78
13F filer change QoQ
-9
Institutional ownership
40.0%
Conviction holders (share of 13F filers)
3.8%
Crowding (high-turnover and private-fund holders)
35.8%
Private-fund adviser ownership
35.6%
Active holders' share change QoQ
+33.2%
Holder tenure
8.1
Price vs estimated holder cost
-24.2%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.1%
Short interest
3 metricsShort interest
15.3%
Latest settlement · 16.0 days to cover
Days to cover
16.0d
Short-squeeze score
73 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—